ALK and anaplastic large cell lymphoma: Given their significance, ALK inhibitors, such as crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib, have gained FDA approval for ALK-altered NSCLCs, with crizotinib also approved for ALK-altered IMTs and ALCL.